文献速递肝病消化道肿瘤与早癌

ASK1/p38轴抑制阻断肝细胞线粒体危险信号释放并抑制肝硬化和肝癌进展

ASK1/ p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
PubMed 文献 · Hepatology · 2024-02-20

该临床前研究在硫代乙酰胺诱导和BALB/c.Mdr2-/-小鼠模型中测试小分子GS-444217抑制ASK1的效果。短期抑制显著减少p38磷酸化、肝细胞死亡和纤维化达50%,长期治疗虽净胶原沉积减少有限,但有效预防肝硬化和肝癌进展。

要点

  • 短期ASK1抑制可减少肝细胞死亡和纤维化达50%
  • 长期ASK1抑制有效预防肝硬化进展
  • ASK1抑制可能成为纤维化肝病的治疗策略

核心结论

  • ASK1抑制通过p38依赖方式阻断濒死肝细胞释放线粒体DNA,保护肝脏免受纤维化。
  • 长期ASK1靶向虽净抗纤维化效果减弱,但有效抑制BALBc/Mdr2-/-小鼠进展为肝硬化和肝癌。

研究设计与样本

  • 临床前体内外研究,使用硫代乙酰胺诱导和BALB/c.Mdr2-/-小鼠肝硬化及肝癌模型。
  • 短期(4-6周)和长期(24-44周)使用小分子GS-444217抑制ASK1,并进行原代肝细胞死亡检测。

主要发现

  • 短期GS-444217治疗在两种模型中显著降低磷酸化p38、肝细胞死亡和纤维化达50%。
  • ASK1或p38抑制可阻断濒死肝细胞释放促纤维化的线粒体DAMP线粒体DNA。
  • 长期(24周)治疗使BALBc.Mdr2-/-模型桥接纤维化中度减少25%,但净胶原沉积未减少。
  • 长期治疗有效预防肝硬化,p21+肝细胞染色减少72%,血清氨水平降低46%,门静脉压力平均6.07 vs 对照组8.53 mm Hg。
  • 延长ASK1抑制至44周使老年BALB/c.Mdr2-/-小鼠肿瘤数量和大小较对照组减少约50%。

临床怎么用

  • 这些数据支持在纤维化肝病中开展ASK1抑制剂的临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Apoptosis Signal-regulating Kinase 1 (ASK1) is activated by various pathological stimuli and induces cell apoptosis through downstream p38 activation. We studied the effect of pharmacological ASK1 inhibition on cirrhosis and its sequelae using comprehensive preclinical in vivo and in vitro systems. APPROACH AND RESULTS: Short-term (4-6 wk) and long-term (24-44 wk) ASK1 inhibition using small molecule GS-444217 was tested in thioacetamide-induced and BALB/c. Mdr2-/- murine models of cirrhosis and HCC, and in vitro using primary hepatocyte cell death assays. Short-term GS-444217 therapy in both models strongly reduced phosphorylated p38, hepatocyte death, and fibrosis by up to 50%. Profibrogenic release of mitochondrial DAMP mitochondrial deoxyribonucleic acid from dying hepatocytes was blocked by ASK1 or p38 inhibition. Long-term (24 wk) therapy in BALBc.Mdr2 - / - model resulted in a moderate 25% reduction in bridging fibrosis, but not in net collagen deposition. Despite this, the development of cirrhosis was effectively prevented, with strongly reduced p21 + hepatocyte staining (by 72%), serum ammonia levels (by 46%), and portal pressure (average 6.07 vs. 8.53 mm Hg in controls). Extended ASK1 inhibition for 44 wk in aged BALB/c. Mdr2-/- mice resulted in markedly reduced tumor number and size by ~50% compared to the control group. CONCLUSIONS: ASK1 inhibition suppresses the profibrogenic release of mitochondrial deoxyribonucleic acid from dying hepatocytes in a p38-dependent manner and protects from liver fibrosis. Long-term ASK1 targeting resulted in diminished net antifibrotic effect, but the progression to liver cirrhosis and cancer in BALBc/ Mdr2- / - mice was effectively inhibited. These data support the clinical evaluation of ASK1 inhibitors in fibrotic liver diseases.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Peng Z, Wei G, Huang P, et al. ASK1/ p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer. Hepatology. 2024. PMID: 38377458. doi:10.1097/HEP.0000000000000801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。